Syed Mahmood, MD
Dr. Mahmood is a physician-scientist with over 13 years of experience working at U.S. and Global pharmaceutical/biotechnology companies, with varying roles leading strategic, translational medicine, clinical development, medical affairs, and operations teams.
Prior to joining Intensity Therapeutics, Dr. Mahmood was the Vice President and Head, Global Medical Affairs, Research and Development at Progenics Pharmaceuticals. Previously, he has held U.S. and global leadership positions of increasing levels of responsibility at Novartis, GlaxoSmithKline, Daiichi Sankyo, and GE Healthcare. Over the course of his career, he has successfully built and led teams and departments responsible for Phase I to III clinical programs for small molecules, biologics and radiopharmaceuticals across many therapeutic areas, including oncology. He has played important roles in multiple development programs and launches, including Progenics’ AZEDRA and PyL, and GSK’s/Novartis’ Tafinlar, Mekinist, Votrient, Luminespib and Buparlisib programs.
Dr. Mahmood received his MD from the George Washington University School of Medicine and Health Sciences, Washington, DC. He completed a medical internship at Aria–Jefferson Health, Philadelphia, PA, and a residency in Nuclear Medicine at Memorial Sloan Kettering Cancer Center, New York, NY. He also served as a PET fellow and an Assistant Professor/Attending Physician in Nuclear Medicine at the Montefiore Medical Center, Bronx, NY, an Attending Physician in Radiology at the University of Pennsylvania, Philadelphia, PA, and an Attending Physician in Jacobi Medical Center-New York City’s Health and Hospitals Corporation Bronx, NY. He is board-certified by the American Board of Nuclear Medicine.